Skip to main content
Diabetes Care logoLink to Diabetes Care
. 2019 Jan 23;42(3):494. doi: 10.2337/dc19-er03

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050

Lennart Tonneijck, Mark M Smits, Marcel HA Muskiet, Trynke Hoekstra, Mark HH Kramer, AH Jan Danser, Piet M ter Wee, Michaela Diamant, Jaap A Joles, Daniel H van Raalte
PMCID: PMC6385692  PMID: 30674545

On page 2048 of the article cited above, the word “increases” was corrected to read “decreases.” The new sentence reads: Notably, a decrease in plasma protein concentration decreases the ultrafiltration coefficient in order to maintain stable GFR (38), but the Gomez estimation does not include this adaptation.

The online version reflects this change.


Articles from Diabetes Care are provided here courtesy of American Diabetes Association

RESOURCES